1
|
Dieu Vuong L, Ngoc Nguyen Q. ABERRANT METHYLATION OF CANCER-RELATED GENES IN VIETNAMESE BREAST CANCER PATIENTS: ASSOCIATIONS WITH CLINICOPATHOLOGICAL FEATURES. Exp Oncol 2023; 45:195-202. [PMID: 37824772 DOI: 10.15407/exp-oncology.2023.02.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Indexed: 10/14/2023]
Abstract
BACKGROUND Epigenetic alteration is one of the most common molecular changes identified in the progression of breast cancer (BC). AIM To study the frequency and relation between methylation of BRCA1, MLH1, MGMT, GSTP1, APC, RASSF1A, p16, WIF, and EGFR and the clinicopathological features in Vietnamese BC patients. MATERIALS AND METHODS Methylation-specific polymerase chain reaction (MS-PCR) and SPSS 20.0 software were utilized in order to identify methylated frequency as well as evaluate its relationship with the patient's clinical features. RESULTS In 162 BC cases, the methylation rates of the selected genes were 53.7%, 22.8%, 38.9%, 34.6%, 29.0%, 46.3%, 20.4%, 18.5%, and 28.4% respectively. In 32 cases of benign breast diseases (BBD) - 12.5%, 15.6%, 6.3%, 3.1%, 12.5%, 21.9%, 3.1%, 15.6% and 3.1%. BC samples displayed higher BRCA1, MGMT, GSTP1, APC, RASSF1A, WIF1, and p16 methylation levels than BBD samples (p < 0.001). Hypermethylation of BRCA1, GSTP1, and RASSF1A was predominant in the invasive ductal carcinoma, while hypermethylation of BRCA1, GSTP1, RASSF1A, WIF-1, and p16 was found to significantly correlate with lymph node metastasis (p < 0.05). Hypermethylation of BRCA1, MGMT, and GSTP1 was more common in stage III (p < 0.05) than in stages I/II, whereas MLH1 methylation was predominant in stage I and APC methylation was less common in stage III (p = 0.03). In addition, methylation of RASSF1A and EGFR was more frequent in younger patients (p < 0.01) than in elder patients. CONCLUSION These data suggest that a gene panel (BRCA1/MGMT/GSTP1) can be used to support the diagnosis and screening of Vietnamese patients' BC with a sensitivity of 70%, and a specificity of 85%.
Collapse
Affiliation(s)
- Linh Dieu Vuong
- Pathology and Molecular Biology Centre, National Cancer Hospital K, 30 Cau Buou Street, Thanh Tri, Hanoi, Vietnam
| | - Quang Ngoc Nguyen
- Pathology and Molecular Biology Centre, National Cancer Hospital K, 30 Cau Buou Street, Thanh Tri, Hanoi, Vietnam.
| |
Collapse
|
2
|
Fedets OM, Dmytruk KV, Adaszek L, Kurlyak IM, Dmytruk OV, Lisiecka U, Winiarczyk S. Polymorphism of glutathione S-transferase P1 of dogs with mammary tumours. Vet Comp Oncol 2023; 21:270-278. [PMID: 36808425 DOI: 10.1111/vco.12885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 01/21/2023] [Accepted: 01/23/2023] [Indexed: 02/23/2023]
Abstract
Mammary tumours constitute more than half of neoplasms in female dogs from different countries. Genome sequences are associated with cancer susceptibility but there is little information available about genetic polymorphisms of glutathione S-transferase P1 (GSTP1) in canine cancers. The aim of this study was to find single nucleotide polymorphisms (SNPs) in GSTP1 of dogs (Canis lupus familiaris) with mammary tumours compared to healthy dogs and to determine the association between GSTP1 polymorphisms and the occurrence of these tumours. The study population included 36 client-owned female dogs with mammary tumours and 12 healthy female dogs, with no previous diagnosis of cancer. DNA was extracted from blood and amplified by PCR assay. PCR-products were sequenced by Sanger method and analysed manually. The 33 polymorphisms were found in GSTP1: 1 coding SNP (exon 4), 24 non-coding SNPs (9 in exon 1), 7 deletions and 1 insertion. The 17 polymorphisms have been found in introns 1, 4, 5 and 6. The dogs with mammary tumours have significant difference from healthy in SNPs I4 c.1018 + 123 T > C (OR 13.412, 95%CI 1.574-114.267, P = .001), I5 c.1487 + 27 T > C (OR 10.737, 95%CI 1.260-91.477, P = .004), I5 c.1487 + 842 G > C (OR 4.714, 95% CI 1.086-20.472, P = .046) and I6 c.2481 + 50 A > G (OR 12.000, 95% CI 1.409-102.207, P = .002). SNP E5 c.1487 T > C and I5 c.1487 + 829 delG also differed significantly (P = .03) but not to the confidence interval. The study, for the first time, showed a positive association of SNPs in GSTP1 with mammary tumours of dogs, that can possibly be used to predict the occurrence of this pathology.
Collapse
Affiliation(s)
- Oleh M Fedets
- Department of Biological and General Chemistry, Stepan Gzhytskyi National University of Veterinary Medicine and Biotechnologies Lviv, Lviv, Ukraine
| | - Kostyantyn V Dmytruk
- Department of Molecular Genetics and Biotechnology, Institute of Cell Biology National Academy of Sciences of Ukraine, Lviv, Ukraine
| | - Lukasz Adaszek
- Department of Epizootiology and Clinic of Infectious Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland
| | - Iryna M Kurlyak
- Department of Biological and General Chemistry, Stepan Gzhytskyi National University of Veterinary Medicine and Biotechnologies Lviv, Lviv, Ukraine
| | - Olena V Dmytruk
- Department of Molecular Genetics and Biotechnology, Institute of Cell Biology National Academy of Sciences of Ukraine, Lviv, Ukraine
- Department of Biotechnology and Microbiology, University of Rzeszow, Rzeszów, Poland
| | - Urszula Lisiecka
- Department of Epizootiology and Clinic of Infectious Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland
| | - Stanislaw Winiarczyk
- Department of Epizootiology and Clinic of Infectious Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland
- National Veterinary Research Institute, Pulawy, Poland
| |
Collapse
|
3
|
Cha HY, Wu Y, Shang LN, Sun F. Association of glutathione thioltransferase P1 ( GSTP1) gene polymorphism with sensitivity to oxaliplatin and traditional Chinese medicine syndrome types in colon cancer patients. Shijie Huaren Xiaohua Zazhi 2021; 29:488-495. [DOI: 10.11569/wcjd.v29.i9.488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Colon cancer has a high incidence, and chemotherapy is still the only treatment for it. Oxaliplatin, as a third generation platinum chemotherapy drug, has a good efficacy in the treatment of colorectal cancer. However, due to the influence of genetic susceptibility, people with different genotypes have different sensitivities to oxaliplatin. As a result, the therapeutic effect varies greatly among different patients.
AIM To explore the association of glutathione sulfhydryl transferase P1 (GSTP1) gene polymorphism with sensitivity to oxaliplatin and traditional Chinese medicine (TCM) syndrome types in colon cancer patients.
METHODS A total of 246 colon cancer patients who received chemotherapy with oxaliplatin-based regimens at our hospital from January 2015 to June 2020 were selected. The Ile105Val polymorphism of GSTP1 gene was detected before chemotherapy, and the curative effect was evaluated after three cycles of chemotherapy. The clinical data and the distribution of GSTP1 genotypes of patients with different chemotherapy effects were compared, and the factors affecting the efficacy of oxaliplatin chemotherapy were analyzed. The distribution of TCM syndrome types of colon cancer patients was also calculated, and the relationship between GSTP1 genotype and TCM syndrome types and syndrome elements was evaluated.
RESULTS There was a polymorphism in the Ile105Val locus of the GSTP1 gene, which conformed to the Hardy-Weinberg equilibrium law and was representative of the population (P > 0.05). After three cycles of oxaliplatin chemotherapy in 246 patients with colon cancer, the total effective rate was 43.90% (108/246). Clinical stage Ⅳ, moderate/well differentiation lymph node metastasis, and GSTP1 genotypes AG and GG were important factors influencing the effect of oxaliplatin chemotherapy in colon cancer patients (P < 0.05). The distribution of TCM syndromes in 118 patients with colon cancer was as follows: Stasis-toxin internal resistance type > Spleen and kidney Yang deficiency type > Qi and blood deficiency type > Damp-heat accumulation type > Liver and kidney Yin deficiency type. There was a statistically significant difference in the distribution of GSTP1 genotypes in patients with blood stasis internal resistance type and Qi and blood deficiency type (P < 0.05). There was a statistically significant difference in the distribution of TCM syndrome types among patients with different GSTP1 genotypes (P < 0.05). The distribution of spleen, lung, and kidney elements of TCM syndromes in patients with different GSTP1 genotypes was significantly different (P < 0.05).
CONCLUSION There is an association between the GSTP1 gene polymorphism and sensitivity to oxaliplatin and TCM syndrome types in colon cancer patients. Therefore, the detection of GSTP1 gene polymorphism is helpful to evaluate the therapeutic effect in patients receiving oxaliplatin as the basic drug chemotherapy, determine the type of TCM syndrome, and provide scientific guidance for individualized treatment of colon cancer.
Collapse
Affiliation(s)
- Hua-Ying Cha
- Department of Medicine, Deqing County Hospital of Traditional Chinese Medicine, Huzhou 313200, Zhejiang Province, China
| | - Yan Wu
- Department of Medicine, Deqing County Hospital of Traditional Chinese Medicine, Huzhou 313200, Zhejiang Province, China
| | - Luo-Nan Shang
- Department of Imaging, Deqing County Hospital of Traditional Chinese Medicine, Huzhou 313200, Zhejiang Province, China
| | - Fang Sun
- Department of Radiotherapy and Chemotherapy, Deqing County Hospital of Traditional Chinese Medicine, Huzhou 313200, Zhejiang Province, China
| |
Collapse
|
4
|
Raafat N, Ismail K, Hawsawi NM, Saber T, Elsawy WH, Abdulmutaleb T, Raafat A, Gharib AF. Glutathione S transferase T1 gene polymorphism and its promoter methylation are associated with breast cancer susceptibility in Egyptian women. Biotechnol Appl Biochem 2021; 69:526-533. [PMID: 33600611 DOI: 10.1002/bab.2129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 02/07/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND Breast cancer (BC) is one of the leading causes of cancer mortality in women. Glutathione S-transferase (GSTT1) is involved in activation of detoxification reactions and catalysis of chemicals conjugation with glutathione. GSTT1 genotype is a limiting factor for some environmental diseases. Epigenetic changes have an essential role in BC through inappropriate interaction between genomic and environmental risk factors. AIM This study was directed to explore the association of BC risk with GSTT1 genetic variations and its methylation status in Egyptian women. DESIGN AND METHODS This study included 100 healthy women as the control group and 100 patients were clinically and histologically diagnosed with breast cancer. All blood samples were used for genomic DNA extraction. GSTT1 genotyping was accomplished by multiplex PCR and methylation-specific PCR was used to analyze the GSTT1 promoter methylation status. RESULTS Breast cancer patients showed significant incidence of null GSTT1 in relation to controls (p = 0.004). GSTT1 gene promoter methylation status showed significant difference between hypermethylated and unmethylated patients when compared with healthy subjects (p = 0.005). GSTT1 promoter methylation status was not significantly associated with null genotype. There was no significant association between GSTT1-null genotypes and BC stage in cases with or without family history, but for promotor methylation, there was significant association with stage III and IV breast cancer disease. CONCLUSION GSTT1 null genetic variant and promoter hypermethylation in the GSTT region of the gene may be considered as critical risk factors for BC in Egyptian women.
Collapse
Affiliation(s)
- Nermin Raafat
- Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Khadiga Ismail
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
| | - Nahed M Hawsawi
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
| | - Taisir Saber
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
| | - Wael H Elsawy
- Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Egypt
| | - Tariq Abdulmutaleb
- Ministry of Health, King Faisal Medical Complex Alpakistany, Taif, Saudi Arabia
| | - Ahmed Raafat
- General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Amal F Gharib
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
| |
Collapse
|
5
|
Silencing of long non-coding RNA LINC01270 inhibits esophageal cancer progression and enhances chemosensitivity to 5-fluorouracil by mediating GSTP1methylation. Cancer Gene Ther 2020; 28:471-485. [PMID: 33199829 DOI: 10.1038/s41417-020-00232-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 08/28/2020] [Accepted: 09/21/2020] [Indexed: 12/17/2022]
Abstract
Esophageal cancer (EC) is a serious digestive malignancy which remains the sixth leading cause of cancer-related deaths worldwide. Emerging evidence suggests the involvement of long non-coding RNAs (lncRNAs) in the tumorigenesis of EC and thus, in this study we explored the potential effects of lncRNA LINC01270 on EC cell proliferation, migration, invasion and, drug resistance via regulation of glutathione S-transferase P1 (GSTP1) methylation. First, we screened out the EC-related differentially expressed lncRNAs, and the expression of our top candidate LINC01270 was quantified in EC tissues and cells. To define the role of LINC01270 in EC progression, we evaluated the proliferation, migration and invasion of EC cells when the LINC01270 was overexpressed or knocked down, in the presence of the GSTP1 methylation inhibitor SGI-1027 and 5-fluorouracil (5-FU). In addition, interaction between LINC01270 and methylation of the GSTP1 promoter was identified. Finally, we assessed transplantable tumor growth in nude mice. LINC01270 was up-regulated and GSTP1 was down-regulated in EC tissues and cells. Silencing of LINC01270 inhibited migration and invasion, and enhanced the sensitivity of 5-FU in EC cells. We found that LINC01270 recruited the DNA methyltransferases DNMT1, DNMT3A and DNMT3B initiating GSTP1 promoter methylation, thereby leading to the proliferation, migration, invasion and drug resistance of EC cells. Moreover, GSTP1 overexpression was observed to reverse the effects of LINC01270 overexpression on EC cells and their response to 5-FU. Taken together, this study shows that inhibition of LINC01270 can lead to suppression of EC progression via demethylation of GSTP1, highlighting this lncRNA as a potential target for EC treatment.
Collapse
|
6
|
Pasha HF, Mohamed RH, Toam MM, Yehia AM. Genetic and epigenetic modifications of adiponectin gene: Potential association with breast cancer risk. J Gene Med 2019; 21:e3120. [PMID: 31415715 DOI: 10.1002/jgm.3120] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 06/22/2019] [Accepted: 08/05/2019] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Adipokines produced by adipose tissue are directly linked to obesity and may contribute to the pathogenesis of cancer. We hypothesized that genetic and epigenetic modifications in the adiponectin (ADIPOQ) gene and their impact on serum ADIPOQ levels may participate in increasing breast cancer (BC) risk. The present study aimed to investigate ADIPOQ +45 T/G gene polymorphism, methylation status at CpG sites -74 nucleotides (nt) and -283 nt of the ADIPOQ gene, and ADIPOQ serum levels in BC obese women. METHODS Serum ADIPOQ was measured by an enzyme-linked immunosorbent assay. ADIPOQ +45 T/G gene polymorphism and ADIPOQ promoter methylation status were determined using a polymerase chain reaction (PCR) and a methylation-specific PCR, respectively, in 120 obese women with BC and 120 age-matched controls. RESULTS ADIPOQ +45 GG genotype carriers had a significant increased risk of developing BC (odds ratio = 6.2, 95% confidence interval = 1.3-29.6, p = 0.02). ADIPOQ gene methylation at site -74 nt resulted in a 1.7-fold increased BC risk. Methylation at site -283 nt resulted in a 1.9-fold increased BC risk. Moreover serum levels of ADIPOQ were significantly decreased in BC patients and down-regulated in the presence of methylation in both examined sites. By contrast, no association between ADIPOQ gene polymorphism and serum ADIPOQ level was detected. Using both methylated sites in one panel detected cancer breast with 76.67% sensitivity and 62.18% accuracy. CONCLUSIONS ADIPOQ +45 T/G polymorphism and ADIPOQ promoter methylation were found to be associated with BC risk in obese Egyptian women.
Collapse
Affiliation(s)
- Heba F Pasha
- Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Randa H Mohamed
- Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Mostafa M Toam
- Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Ahmed M Yehia
- General surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| |
Collapse
|
7
|
Moghazy TF, ElAttar HA, Eldeeb MK, Rashad RM, Farouk AM, Farag AM. Methylation of Glutathione-S-Transferase P1 Promotor in Egyptian Females with Breast Cancer. Asian Pac J Cancer Prev 2019; 20:2523-2530. [PMID: 31450928 PMCID: PMC6852835 DOI: 10.31557/apjcp.2019.20.8.2523] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Indexed: 12/24/2022] Open
Abstract
Background: Breast cancer (BC) is the second most common cancer after the lung cancer worldwide and number one killing cancer in Egyptian females . It is a multifactorial disease driven by different environmental, hormonal, genetic and epigenetic factors. Epigenetic alterations have been studied in cancer breast. Role of GSTP1 promotor methylation in breast cancer has been studied in different ethnic groups. Objectives: Current study aimed at studying the methylation status of the promotor region of glutathione-S-transferase P1 in breast ductal carcinoma of a cohort group of Egyptian females and its correlations with histopathological and prognostic parameters. Methods: Control group included 15 fresh normal breast tissues taken from BC female patients after leaving a clearly defined safety margin and a Patient group included confirmed 35 fresh breast ductal carcinoma tissue biopsies taken from female patients postoperatively. To all patients clinical examination, radiological examination (plain X-ray chest and or CT scan, ultrasonography of abdomen and pelvis were done), in addition to histopathological examination, typing, grading and staging of tumour, hormonal receptors status and molecular typing of breast mass. GSTP1 methylation status was evaluated using methyl specific polymerase chain reaction. Results: Statistical significant increase was found in methylation status of GSTP1 promotor gene in BC cases than that in control group, (60% of patients samples had methylated GSTP1 promotor vs only 6.7% of controls) (p= >0.001). No association was found between GSTP1 promotor methylation status and the poor prognostic factors neither with hormonal profile nor molecular type. However, GSTP1 promotor methylation were two times higher in postmenopausal than premenopausal cases and three times higher in late grade (III). Also GSTP1 promotor methylation was 2.4 times higher in Her2 positive cases than either ER or PR positive cases. Conclusion: Glutathione-S-Transferase P1 Promotor methylation plays a role in breast cancer development.
Collapse
Affiliation(s)
- Thanaa Fathy Moghazy
- Department of Chemical Pathology, Medical Research Institute, Alexandria University, Egypt.
| | - Hoda Aly ElAttar
- Department of Chemical Pathology, Medical Research Institute, Alexandria University, Egypt.
| | - Mona Kamal Eldeeb
- Department of Chemical Pathology, Medical Research Institute, Alexandria University, Egypt.
| | - Radwa Mohammed Rashad
- Department of Chemical Pathology, Medical Research Institute, Alexandria University, Egypt.
| | - Ayman Mohamed Farouk
- Department of Clinical and Rxperimental Surgery, Medical Research Institute, Alexandria University, Egypt
| | - Assmaa Mostafa Farag
- Department of Chemical Pathology, Medical Research Institute, Alexandria University, Egypt.
| |
Collapse
|
8
|
Dong SC, Sha HH, Xu XY, Hu TM, Lou R, Li H, Wu JZ, Dan C, Feng J. Glutathione S-transferase π: a potential role in antitumor therapy. Drug Des Devel Ther 2018; 12:3535-3547. [PMID: 30425455 PMCID: PMC6204874 DOI: 10.2147/dddt.s169833] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Glutathione S-transferase π (GSTπ) is a Phase II metabolic enzyme that is an important facilitator of cellular detoxification. Traditional dogma asserts that GSTπ functions to catalyze glutathione (GSH)-substrate conjunction to preserve the macromolecule upon exposure to oxidative stress, thus defending cells against various toxic compounds. Over the past 20 years, abnormal GSTπ expression has been linked to the occurrence of tumor resistance to chemotherapy drugs, demonstrating that this enzyme possesses functions beyond metabolism. This revelation reveals exciting possibilities in the realm of drug discovery, as GSTπ inhibitors and its prodrugs offer a feasible strategy in designing anticancer drugs with the primary purpose of reversing tumor resistance. In connection with the authors' current research, we provide a review on the biological function of GSTπ and current developments in GSTπ-targeting drugs, as well as the prospects of future strategies.
Collapse
Affiliation(s)
- Shu-Chen Dong
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Huan-Huan Sha
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Xiao-Yue Xu
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Tian-Mu Hu
- Department of Biological Science, Purdue University, West Lafayette, IN, USA
| | - Rui Lou
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Huizi Li
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Jian-Zhong Wu
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Chen Dan
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| | - Jifeng Feng
- Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China, ;
| |
Collapse
|
9
|
Vu TL, Nguyen TT, Doan VTH, Vo LTT. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer. Asian Pac J Cancer Prev 2018; 19:1887-1893. [PMID: 30049201 PMCID: PMC6165660 DOI: 10.22034/apjcp.2018.19.7.1887] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 05/03/2018] [Indexed: 12/13/2022] Open
Abstract
Objective: This study investigated the DNA promoter methylation profiles of BRCA1, RASSF1A and GSTP1 genes, both individually and in an integrative manner in order to clarify their correlation with clinicopathological parameters of breast cancer from Vietnamese patients, and establish new potential integrative methylation biomarkers for breast cancer detection. Material and methods: The methylation frequencies of BRCA1, RASSF1A and GSTP1 were analyzed by methylation specific polymerase chain reaction (MSP) in 70 specimens of breast carcinomas and 79 pairs of tumor and matched adjacent normal tissues from breast cancer patients. Results: All the three analyzed genes showed a concordance concerning their promoter methylation in tumor and adjacent normal tissue. The methylation of BRCA1, RASSF1A and GSTP1 was found in 58.23 %, 74.68 % and 59.49 % of tumor tissues and 51.90 %, 63.29 % and 35.44 % of corresponding adjacent tissues, respectively. When each gene was assessed individually, only the methylation of GSTP1 was significantly associated with tumor tissues (p=0.003). However, the methylation frequency of at least one of the three genes and the methylation frequency of all the three genes both showed significant association with tumor (p=0.008 and p=0.04, respectively). The methylation of BRCA1 was found to be significantly associated with tumor grade (p=0.01). Conclusion: This study emphasized that the panel of the three genes BRCA1, RASSF1A and GSTP1 can be further developed as potential biomarkers in diagnosis and classification of breast cancer in Vietnamese women.
Collapse
Affiliation(s)
- Trang Lan Vu
- Sorbonne University, UPMC Univ. Paris 06, École Normale Supérieure, PSL Research University, CNRS, INSERM, APHP, Laboratoire des Biomolécules (LBM), Paris, France.
| | | | | | | |
Collapse
|